Vir Biotechnology (NASDAQ:VIR) EVP Mark Eisner Sells 2,089 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Mark Eisner sold 2,089 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $7.45, for a total transaction of $15,563.05. Following the sale, the executive vice president directly owned 157,529 shares of the company’s stock, valued at $1,173,591.05. This represents a 1.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Vir Biotechnology Trading Up 27.7%

VIR opened at $9.49 on Wednesday. The stock has a market capitalization of $1.32 billion, a P/E ratio of -3.00 and a beta of 1.69. Vir Biotechnology, Inc. has a 12 month low of $4.16 and a 12 month high of $10.29. The firm’s fifty day simple moving average is $6.80 and its 200 day simple moving average is $5.99.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.11. The firm had revenue of $64.07 million for the quarter, compared to the consensus estimate of $19.91 million. Vir Biotechnology had a negative return on equity of 47.14% and a negative net margin of 638.88%.The company’s revenue for the quarter was up 417.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.76) EPS. On average, equities research analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Vir Biotechnology

Large investors have recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new position in Vir Biotechnology during the second quarter worth $35,000. FNY Investment Advisers LLC bought a new position in shares of Vir Biotechnology in the 3rd quarter valued at about $38,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Vir Biotechnology by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock worth $41,000 after purchasing an additional 1,390 shares during the last quarter. UMB Bank n.a. raised its holdings in shares of Vir Biotechnology by 1,418.7% in the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock valued at $43,000 after purchasing an additional 6,597 shares during the period. Finally, Federated Hermes Inc. raised its holdings in shares of Vir Biotechnology by 153.8% in the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock valued at $46,000 after purchasing an additional 4,899 shares during the period. Institutional investors and hedge funds own 65.32% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on VIR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Monday, December 22nd. Raymond James Financial raised shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price objective on the stock in a research report on Tuesday. Evercore restated an “outperform” rating and set a $18.00 target price on shares of Vir Biotechnology in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Vir Biotechnology in a research report on Tuesday, December 30th. Finally, Needham & Company LLC boosted their price target on shares of Vir Biotechnology from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.88.

Key Vir Biotechnology News

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas strategic collaboration: Vir announced a global co‑development/co‑commercialization deal for prostate cancer candidate VIR‑5500 with $335M upfront/near‑term payments and up to $1.37B in milestones plus split U.S. economics — a major de‑risk and commercial validation for the program. Astellas and Vir Biotechnology Announce Global Strategic Collaboration
• Positive Sentiment: Encouraging Phase 1 VIR‑5500 data: Updated trial results show a favorable safety profile and meaningful activity (reported higher‑dose ORR of ~45%), underpinning the asset value and the Astellas deal. Vir Biotechnology Reports Positive Updated Phase 1 Results for VIR-5500
• Positive Sentiment: Quarterly beat and revenue acceleration: Q4 EPS beat estimates and revenue of $64.1M far exceeded expectations (~$19.9M), reflecting strong year‑over‑year growth and better near‑term commercial performance. Vir Biotechnology Q4 Earnings Highlights
• Positive Sentiment: Analyst upgrade/target increases: Needham raised its price target (to $18) and other firms reiterated/upgraded coverage, supporting upside expectations. PT Raised to $18 at Needham
• Neutral Sentiment: Broad media amplification: Extensive coverage (Forbes, Seeking Alpha, MSN) is increasing visibility and trading volume but does not change fundamentals by itself. What’s Happening With VIR Stock?
• Neutral Sentiment: Company disclosures: The earnings call transcript and slide deck provide added pipeline and cash‑position detail for investors to model future milestones and spend. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Proposed public offering: Vir filed to sell additional common stock — proceeds would strengthen the balance sheet but the offering is dilutive and can weigh on near‑term shares. Proposed Public Offering
• Negative Sentiment: Insider selling: Multiple insiders (including the CEO and several senior officers) reported stock sales on Feb. 23 — notable for sentiment and potential supply into the market. Insider Sales Report
• Negative Sentiment: Ongoing losses and wide negative margins: Despite revenue momentum and partnerships, Vir reported a sizable 2025 net loss and negative margins, making long‑term upside contingent on execution and milestone payments. 2025 Financial Results and Corporate Update

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.